ResearcherInstitut Jules BordetActive in the last 2 years

Ahmad Hussein Awada

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7412-9163; OpenAlex author ID A5010064853. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2024: 1 paper

Papers 1

Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pan… Last author DOI 10.1158/1078-0432.ccr-24-0645 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Rikke Løvendahl Eefsen · 1 shared paper, 2024 · strength 0.17
- Paper Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel … DOI 10.1158/1078-0432.ccr-24-0645 ↗
Dirk Arnold · 1 shared paper, 2024 · strength 0.17
- Paper Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel … DOI 10.1158/1078-0432.ccr-24-0645 ↗
Per Pfeiffer · 1 shared paper, 2024 · strength 0.17
- Paper Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel … DOI 10.1158/1078-0432.ccr-24-0645 ↗
Eric Van Cutsem · 1 shared paper, 2024 · strength 0.17
- Paper Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel … DOI 10.1158/1078-0432.ccr-24-0645 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.